Stock Track | Krystal Biotech Soars 5.85% Premarket on Stellar Q4 Results, Pipeline Progress

Stock Track

Feb 19, 2025

Shares of Krystal Biotech Inc. (KRYS) surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.

The biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).

For the full year 2024, VYJUVEK net product revenue skyrocketed 473% to $290.5 million. Krystal ended the year with a robust balance sheet, holding $749.6 million in cash and investments to fund its ambitious drug development plans.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1164307551"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164307551\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164307551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-19 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164307551","market":"hk","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Soars 5.85% Premarket on Stellar Q4 Results, Pipeline Progress","media":"Stock Track","content":"<p>Shares of Krystal Biotech Inc. (KRYS) surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.</p>\n\n<p>The biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).</p>\n\n<p>For the full year 2024, VYJUVEK net product revenue skyrocketed 473% to $290.5 million. Krystal ended the year with a robust balance sheet, holding $749.6 million in cash and investments to fund its ambitious drug development plans.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Soars 5.85% Premarket on Stellar Q4 Results, Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Soars 5.85% Premarket on Stellar Q4 Results, Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-19 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Krystal Biotech Inc. (KRYS) surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.</p>\n\n<p>The biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).</p>\n\n<p>For the full year 2024, VYJUVEK net product revenue skyrocketed 473% to $290.5 million. Krystal ended the year with a robust balance sheet, holding $749.6 million in cash and investments to fund its ambitious drug development plans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1164307551","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164307551","pubTimestamp":1739976004,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Krystal Biotech Inc.  surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.The biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epid","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"股票赛道Krystal Biotech盘前飙升5.85%，第四季度业绩出色，管道进展顺利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Shares of Krystal Biotech Inc. (KRYS) surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.\nThe biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).\nFor the full year 2024, VYJUVEK net product revenue skyrocketed 473% to $290.5 million. Krystal ended the year with a robust balance sheet, holding $749.6 million in cash and investments to fund its ambitious drug development plans.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}